Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: J Orthop Res. 2017 Nov 28;36(5):1487–1497. doi: 10.1002/jor.23781

Figure 6. The Phlpp inhibitor, NSC117079, induces glycosaminoglycan synthesis, ACAN and HAS2 gene expression and kinase phosphorylation in human articular cartilage explants.

Figure 6

A. Articular cartilage explants from human patients undergoing knee replacement (n=11) were placed in culture with 5μM NSC117079 for 14 days. Medium was changed every 3 to 4 days. GAG content in the medium was measured with the Chondrex Glycoaminoglycans Assay. *p<0.05. B. Human articular cartilage explants treated with the Phlpp inhibitor were embedded in paraffin, sectioned and stained with Alcian blue. Scale bars equal 100 microns. C. RT-qPCR for ACAN and HAS2 mRNA from human articular cartilage chondrocytes that were incubated in chondrogenic medium and the Phlpp inhibitor for 14 days. n=5, *p < 0.05. D. Western blots of proteins extracted from human articular chondrocytes that were incubated in chondrogenic medium and the Phlpp inhibitor NSC117079 for 14 days. E. Human articular cartilage explants treated with the Phlpp inhibitor were embedded in paraffin, sectioned, and subjected to immunohistochemistry with antibodies for the indicated proteins. Scale bars equal 100 microns.